Xilio Therapeutics/XLO

$0.72

9.09%
-
1D1W1MYTD1YMAX

About Xilio Therapeutics

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built its geographically precise solutions platform to rapidly engineer molecules, including cytokines and other biologics. Its tumor-activated, clinical-stage product candidates are XTX202, an interleukin 2 (IL-2), therapy, XTX301, an interleukin 12 (IL-12), therapy and XTX101. Its XTX101 is designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment and improve upon the therapeutic index of existing anti-CTLA-4 therapies. Its XTX101 in an ongoing Phase I clinical trial in patients with advanced solid tumors. XTX202 is an investigational tumor-activated beta-gamma biased (non-alpha), engineered IL-2 molecule designed to potently stimulate CD8+ effector T cells and NK cells without concomitant stimulation of regulatory T cells.

Ticker

XLO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rene Russo

Employees

81

Headquarters

Waltham, United States

XLO Metrics

BasicAdvanced
$19.84M
Market cap
-
P/E ratio
-$2.96
EPS
-
Beta
-
Dividend rate

What the Analysts think about XLO

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 2 analysts.
663.89% upside
High $6.00
Low $5.00
$0.72
Current price
$5.50
Average price target

XLO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-16.7M
-13.47%
Profit margin
0%
-

XLO Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 24.46%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.82
-$0.83
-$0.70
-$0.61
-
Expected
-$0.79
-$0.89
-$0.87
-$0.81
-$0.74
Surprise
4.46%
-6.29%
-19.31%
-24.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Xilio Therapeutics stock

Buy or sell Xilio Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing